Autres langues CRISPR Therapeutics AG

Actions

CRSP

CH0334081137

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 02/05/2024			Varia. 5j.	Varia. 1 janv.
55,07 ^USD	+2,34%		+2,49%	-12,03%

18/04	CRISPR THERAPEUTICS AG : Citigroup toujours positif	ZM
17/04	Un initié de Crispr Therapeutics a vendu des actions pour une valeur de 1 173 232 $, selon un récent dépôt auprès de la SEC	MT

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

CRISPR Therapeutics to Present Oral Presentation at the American Society of Gene and Cell Therapy 2024 Annual Meeting	23/04
CRISPR Therapeutics to Present Oral Presentation at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting	22/04
Crispr Therapeutics Insider Sold Shares Worth $1,173,232, According to a Recent SEC Filing	17/04
Harvard University: How to realize immense promise of gene editing	17/04
CRISPR Therapeutics to Present at the Annual Needham Virtual Healthcare Conference	03/04
CRISPR Therapeutics to Present at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting	01/04
Recent Appellate Decision Overturns Revocations Of Broad Institute CRISPR-Cas9 Patents	26/03
CRISPR Therapeutics Proposes New Appointment to the Board of Directors	13/03
CRISPR Therapeutics Swings to Q4 Profit, Revenue Increases	21/02
CRISPR Therapeutics AG Reports Earnings Results for the Full Year Ended December 31, 2023	21/02
Earnings Flash (CRSP) CRISPR THERAPEUTICS AG Reports Q4 Revenue $201.2M	21/02
Earnings Flash (CRSP) CRISPR THERAPEUTICS AG Posts Q4 EPS $1.10	21/02
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results	21/02
CRISPR Therapeutics AG Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	21/02
Crispr Therapeutics Ag Insider Sold Shares Worth $1,607,177, According to a Recent SEC Filing	16/02
CRISPR Therapeutics to Present at the Citi 2024 Virtual Oncology Leadership Summit	15/02
CRISPR Therapeutics - European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY, for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia	14/02
CRISPR Therapeutics to Sell About $280 Million of Common Shares	13/02
CRISPR Therapeutics Announces $280 Million Registered Direct Offering	13/02
Vertex secures European approval for CRISPR cell therapy	13/02

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues CRISPR Therapeutics AG

Actions

CRSP

CH0334081137

Autres langues

Filtres